Micropos Medical (MPOS) Q3 2026 earnings summary

Executive summary

• Q3 activity was seasonally quieter in Europe, while commercial progress included new Spanish installations, a first MUSC patient, growing UK use and Swiss customer discussions.

• Raypilot System had ~16 active customers, installations underway at ~4 more clinics and ~450 patients treated to date.

Financial highlights

• Q3 2026 net sales were 679 TSEK vs 743 TSEK YoY; result after financial items was -5,594 TSEK vs -5,814 TSEK, with EPS of -SEK 0.03 in both periods.

• Jan-Sep 2026 net sales were 2,272 TSEK vs 6,723 TSEK; result after financial items was -22,052 TSEK vs -15,604 TSEK, and EPS was -SEK 0.13 vs -SEK 0.09.

• Jan-Sep operating loss widened to 22,164 TSEK from 15,331 TSEK; 538 TSEK of development work was capitalized, vs 0 TSEK a year earlier.

• Jan-Sep cash flow was +1,490 TSEK vs +8,570 TSEK; period-end cash was 11,309 TSEK vs 16,560 TSEK.

Outlook and guidance

• Priorities are to increase patient volumes at existing clinics, embed Raypilot System in routine care and develop recurring sales of consumables.

• Product development will accelerate as regulatory work eases, with customer experience informing system functionality and clinical workflows.